Pulmonary Embolism
Pipeline by Development Stage
Respiratory is a $39.4B mature market dominated by established inhalers and combination therapies with significant patent cliff risk.
Key Trends
- Consolidation around GSK's triple-therapy franchises (Trelegy, Breo, Anoro)
- Major patent expirations 2026-2031 creating $7.8B revenue cliff
- High clinical trial activity (4,862 trials) suggesting pipeline innovation despite market maturity
Career Verdict
Respiratory offers stable commercial careers but limited growth upside; best for professionals seeking established markets with strong commercial infrastructure rather than innovation-driven advancement.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 46% | Launch | Growing | 15.0yr |
| 2 | TRULICITY (dulaglutide) | Eli Lilly and Company | $7.4B | 19% | Peak | Stable | |
| 3 | TRELEGY ELLIPTA (fluticasone/umeclidinium/vilanterol) | GSK | $4.5B | 11% | Peak | Declining | 4.9yr |
| 4 | CREON (pancrelipase) | AbbVie | $1.5B | 4% | Approaching LOE | Declining | |
| 5 | BREO ELLIPTA (fluticasone/vilanterol) | GSK | $1.4B | 4% | Peak | Declining | 4.9yr |
Drug Class Breakdown
dominant market driver
fragmented portfolio
rapidly expanding
legacy product
patent cliff approaching
mature maintenance therapy
Career Outlook
StableRespiratory is a stable, mature market suitable for commercial and medical affairs professionals seeking established career paths, but offers limited growth or innovation-focused opportunities. The impending patent cliff ($7.8B+ revenue at risk 2026-2031) will drive near-term restructuring and consolidation, potentially reducing headcount in 2027-2028. Professionals should expect strong compensation in Medical Affairs and field roles but limited advancement into strategic or R&D positions.
Breaking In
New graduates should prioritize commercial, field-based, or Medical Affairs roles over R&D; respiratory offers structured training and stable compensation but limited innovation exposure, so pair this experience with cross-therapeutic skill-building for long-term mobility.
For Experienced Professionals
Experienced professionals should evaluate whether to maximize earnings in this mature, stable market or transition to higher-growth areas (oncology, cell therapy); respiratory consolidation 2027-2030 will reduce senior-level opportunities, so consider strategic moves before patent cliff impacts headcount.
In-Demand Skills
Best For
Hiring Landscape
The respiratory sector shows modest hiring momentum (510 jobs across tracked positions) concentrated in commercial and engineering roles, with AstraZeneca and GSK leading. Medical Affairs positions command premium salaries ($314K avg) but represent only 3% of openings, reflecting the mature market's focus on sales execution over innovation. Hiring velocity is moderate and reflects market consolidation rather than expansion, suggesting limited career progression opportunities for early-to-mid career professionals.
Top Hiring Companies
By Department
Respiratory hiring favors commercial and field-based roles over R&D; Medical Affairs roles offer premium compensation but are scarce, making this area competitive for specialized talent.
Competitive Landscape
31 companies ranked by most advanced pipeline stage
+1 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 19,284 patients across 50 trials
Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital
Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism
Multicenter, Nonrandomized, Prospective Study of Pulmonary Embolism Removal With the AngioJet 6F Ultra System
Is Using Fondaparinux (Blood Thinner) to Treat Lung Clot Cheaper Than Traditional Therapy
Post-marketing Study of Monteplase ("Cleactor") in Patients With Acute Pulmonary Embolism
Detection of Pulmonary Embolism With CECT
Protection From Pulmonary Embolism With the Permanent OptEase™ Filter (PROOF)
Pulmonary Embolism International THrOmbolysis Study-3
tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden
Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy
SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism
Effect of iNO in Patients With Submassive and Massive PE
DS-9231 in Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE)
Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism
First - In - Man Study to Assess the Safety and Feasibility of The Bashir™ Endovascular Catheter for the Treatment of Acute Pulmonary Embolism
Evaluation of the Magneto eTrieve™ PE Kit for Endovascular Thrombectomy in Subjects With Acute Pulmonary Embolism
Cleaner Long-tErm Assessment Registry - Venous Insights and Efficacy With eXtended Tracking
Non-Invasive Measurement of Cardiac Output and Stroke Volume in PE
Inari VISION Registry
CLEANer Aspiration for Pulmonary Embolism
The PERSEVERE Study
Selective Pulmonary-artery Intervention to Reduce Acute Right-heart tEnsion-II
Dead Space and Inhaled Nitric Oxide in Pediatric Acute Respiratory Distress Syndrome
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
The RAPID - PE Study: RESCUE Advanced Protocol for the Treatment of Pulmonary Embolism
The Study of Monitoring and Dosing Guidance of Direct Oral Anticoagulants Based on Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics
The PEERLESS II Study
Aventus Thrombectomy System Pulmonary Embolism Clinical Study
Comparing Electrical Impedance Tomography to Computed Tomographic Angiography
FlowTriever2 Pulmonary Embolectomy Clinical Study
Prospective Validation of an Acute Pulmonary Embolism Severity and Prognosis Prediction Model
US Pivotal Clinical Study of the Adient Absorbable Filter for the Prevention of Pulmonary Embolism
Endovascular Engineering ENGULF Study
Validation of SEARCH, a Novel Hierarchical Algorithm to Define Long-term Outcomes After Pulmonary Embolism
Evaluating the Safety and Efficacy of the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE for Treatment of Acute Pulmonary Embolism
Ventilation and Perfusion Scan in Pulmonary Embolism Following Catheter Directed Thrombectomy Versus Anticoagulation Alone
The PEERLESS Study
Treatment of Low-Risk Submassive Pulmonary Embolism With FlowTriever
Evaluation of the Safety and Performance of Magneto PE Kit
Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System
Rivaroxaban in Elderly Chinese Venous Thromboembolism Patients
Pulmonary Embolism Prognosis Model
A Prospective Study for the Treatment of Severe Pulmonary Embolism With Pharmacodynamic Thrombectomy
Evaluating the Safety and Efficacy of the Indigo® Aspiration System in Acute Pulmonary Embolism
FlowTriever Pulmonary Embolectomy Clinical Study
Predicting the Safety and Effectiveness of Inferior Vena Cava Filters
Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography.
The Angel® Catheter Pivotal Clinical Trial
The SENTRY Clinical Study
VenaTech Convertible Vena Cava Filter U.S. Multi-Center Clinical Trial
Related Jobs in Respiratory
Peripheral Territory Manager East Poland (m/f/d)
Neurovascular Territory Manager London (m/f/d) - London
Tender, Offer and Contract Specialist for the Nordics (m/f/d)
Tender, Offer and Contract Specialist (m/f/d) - based in Germany or Poland
Neurovascular Product Marketing Manager for UK, Benelux & Nordics (m/f/d) - based in the UK
Therapy Development Specialist - South Florida
Phase Legend
Key Insights
Related Indications
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.